Metabolism-programming mRNA-lipid nanoparticles remodel the immune microenvironment to improve immunotherapy against MAFLD
- 3 December 2025
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (827) , eadv2293
Abstract
Metabolic dysfunction–associated fatty liver disease (MAFLD), a leading cause of hepatocellular carcinoma (HCC), poses a formidable therapeutic challenge because of the metabolic stress–induced aberrant immune microenvironment. However, no effective pharmacological therapies for the liver microenvironment remodeling in MAFLD are now available. Here, we developed a lipid nanoparticle (Def-LNP) that incorporates vitamin E–derived phosphatidylcholine (VEPC). Def-LNP effectively ameliorated the hepatic oxidative microenvironment to achieve sustained localized expression of target mRNA in hepatocytes in preclinical models, outperforming a commercially used LNP formulation. In vivo delivery efficiency, stability, and biosafety of Def-LNP were validated in various mammalian models, including mice, pigs, and nonhuman primates. Using clinical samples, we identified a pronounced correlation between T cell protein tyrosine phosphatase (TCPTP) and MAFLD pathogenesis. The administration of Def-LNP loaded with TCPTP-encoding mRNA (Def-LNP@mRNA TCPTP ) suppressed signal transducer and activator of transcription signaling in the hepatocytes of MAFLD mice, leading to hepatic metabolic reprogramming and immunological reconfiguration, a characteristic that is prominently lacking in conventional mRNA-based protein replacement therapy. In preclinical models, the administration of Def-LNP@mRNA TCPTP successfully eliminated steatohepatitis, impeded hepatocarcinogenesis, and improved the therapeutic responsiveness of HCC to cancer vaccine and immune checkpoint blockade therapy. Def-LNP@mRNA TCPTP represents a potential therapeutic strategy for MAFLD and MAFLD-related HCC, potentially offering treatment paradigms for immunotherapy for HCC and metabolic liver diseases.Keywords
Funding Information
- National Natural Science Foundation of China (22175107)
- National Natural Science Foundation of China (22305140)
- National Natural Science Foundation of China (82273338)
- National Natural Science Foundation of China (32321002)
- National Natural Science Foundation of China (92359304)
- Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park (Z231100007223007)
- National Key R&D Program of China (2023YFE0204900)
- National Key R&D Program of China (2023YFC3403100)
- National Key R&D Program of China (2020YFA0804300)
- Starry Night Science Fund of Zhejiang University Shanghai Institute for Advanced Study (SN-ZJU-SIAS-006)
This publication has 47 references indexed in Scilit:
- Magnetic responsive hydroxyapatite scaffold modulated macrophage polarization through PPAR/JAK-STAT signaling and enhanced fatty acid metabolismBiomaterials, 2023
- The JAK-STAT pathway at 30: Much learned, much more to doCell, 2022
- Understanding Nanomaterial–Liver Interactions to Facilitate the Development of Safer NanoapplicationsAdvanced Materials, 2022
- Endogenous vitamin E metabolites mediate allosteric PPARγ activation with unprecedented co-regulatory interactionsCell Chemical Biology, 2021
- Lipid-based nanoparticle technologies for liver targetingAdvanced Drug Delivery Reviews, 2020
- Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCCCell, 2018
- CD8+ T Cells Orchestrate pDC-XCR1+ Dendritic Cell Spatial and Functional Cooperativity to Optimize PrimingImmunity, 2017
- ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell HomeostasisCell, 2015
- Metabolic Activation of Intrahepatic CD8+ T Cells and NKT Cells Causes Nonalcoholic Steatohepatitis and Liver Cancer via Cross-Talk with HepatocytesCancer Cell, 2014
- Hepatic Oxidative Stress Promotes Insulin-STAT-5 Signaling and Obesity by Inactivating Protein Tyrosine Phosphatase N2Cell Metabolism, 2014